Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia 6Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Leukemia, Promyelocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Anemia, Refractory, with Excess of Blasts 2Preleukemia 1Neutropenia 1Myeloproliferative Disorders 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Peripheral Blood Stem Cell Transplantation 49Mycophenolic Acid 39Busulfan 38Tacrolimus 37Cyclosporine 33Antilymphocyte Serum 33Whole-Body Irradiation 32Filgrastim 28Methotrexate 27Radiotherapy 20Melphalan 18Cytarabine 17fludarabine 16Etoposide 16Methylprednisolone 14ruxolitinib 11sargramostim 9Flow Cytometry 9Cyclosporins 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 9thymoglobulin 8Sirolimus 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Azacitidine 8merphos 7Decitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloproliferative Disorders × lintuzumab × Clear all
NCT00283114 2014-12-18

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Seagen Inc.

Phase 1 Completed
82 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡